Nuclear Medicine Radiopharmaceuticals Market PowerPoint PPT Presentations

The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.

The global Radiopharmaceuticals/Nuclear Medicine Market was valued at US$ 5605 Million in 2022 and is anticipated to grow at US$ 9327 Million by 2029 recording a CAGR of 9.3% during the forecast period 2023-2029. Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=17441

In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Nuclear Medicine/Radiopharmaceuticals Report by Material, Application, and Geography Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

This report studies the global market size of Radiopharmaceuticals in Nuclear Medicine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Radiopharmaceuticals in Nuclear Medicine in these regions.

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021).

Nuclear Medicine/ Radiopharmaceuticals Market is expected to garner $8,207.5 million by 2022. The market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.

The world radiopharmaceuticals market is expected to generate revenue of $8,207.5 million by 2022, the market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.

This report studies the European nuclear medicine/radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period (2015 to 2020).

Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.

This report studies the Asia-Pacific nuclear medicine market over the forecast period of 2012-2017. The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%. Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimer’s disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012.

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and a pplications.Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Germany, France, Italy, Spain, U.K., Russia, and Rest of Europe) to provide in-depth information on the European scenario.

Radiopharmaceuticals Market Analysis

The global nuclear medicine equipment market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.8% during 2024-2032. More Info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market

The Asia-Pacific nuclear medicine market size was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028.

The Business Research Company offers nuclear medicine diagnostics market research report 2023 with industry size, share, segments and market growth

According to the latest research report by IMARC Group, The global nuclear medicine equipment market size reached US$ 2.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 6.65% during 2023-2028. More Info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market

Nuclear Medicine Equipment Market size is estimated to reach $2.3 billion by 2027, growing at a CAGR of 3.9% during the forecast period 2022-2027.

The Asia-Pacific nuclear medicine market size was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028.

Radiopharmaceuticals is a medical specialty that uses specific radiotracers, and have emerged as an efficient imaging technology in the field of nuclear medicine. The non-invasive nature of radiopharmaceuticals has quickened the diagnosis of various diseases such as cardiovascular diseases, neurological disorders, and cancers.

Looking forward, the nuclear medicine equipment market value is projected to reach a strong growth during the forecast period (2022-2027). More info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market

The Radiopharmaceutical/Nuclear Medicine Market Report offers a complete picture of industry trends and factors along with quantitative data based on historical data and from various sources. Apart from this, the report also provides the market outlook, growth, share, size, opportunity and forecast during 2019-2025. Further, the report focuses on competitive landscape including company profiles of leading key players along with industry demand, future capacities, key mergers & acquisitions, financial overview in the global market of radiopharmaceutical/nuclear medicine.

Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017

[No of pages - 346 ] Browse 142 market tables and 44 figures/charts on Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13),[SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017

In the past few years, more efficient therapeutic nuclear medicines have been launched, which have shown positive results for the treatment of various types of cancer. For instance, the launch of Xofigo (Radium-223) by Bayer for the treatment of prostate cancer and the launch of Lutathera (Lutetium-177) for the treatment of neuroblastoma and synovitis has created growth opportunities for the therapeutic nuclear medicines market over the forecast period.

The global radiopharmaceuticals market size was valued at $5.2 billion in 2022, and is projected to reach $13.7 billion by 2032, growing at a CAGR of 10.2% from 2023 to 2032.

Radiopharmaceuticals Market

The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Radiopharmaceuticals, also known as nuclear medicines, are used in applications such as lymphoma and bone metastasis. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures.

marketreportslibrary.com has released a new "North American Nuclear Medicine or Radiopharmaceuticals Market" report for the upcoming year, that includes major growth is projected over the forecasting period.

The global radiopharmaceuticals market was worth USD 4.31 Billion in 2020 and is further projected to reach USD 6.43 Billion by 2027, at a CAGR of 6.0% during 2021-2027 (forecast period).

The radiopharmaceuticals market is projected to reach US$ 13,818.17 million by 2028 from US$ 7,550.74 million in 2021; it is expected to grow at a CAGR of 9.0% from 2021 to 2028.

Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017

Press Release on “Nuclear Medicine/Radiopharmaceuticals market- Size, Share, Trends Forecast 2022” added by Research Trades to its database. In this report, the global Nuclear Medicine/Radiopharmaceuticals market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Get Sample Copy of this report @ http://www.researchtrades.com/request-sample/1086022

This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period (2015 to 2020).

According to #TechSci Research report, Global Nuclear Imaging Equipment Market stood at USD4054.46 million in 2020 and is expected to grow at a CAGR of 6.51% by 2026. Gain More Insight: https://bit.ly/3v29zB4 Get Sample Report: https://bit.ly/3KdYyVJ Press Release: https://bit.ly/3LGMv3y Website: https://www.techsciresearch.com/ Market Research News: https://techsciblog.com/

The report covers the major unsaturated polyester resin (UPR) markets including Orthophthalic, Isophthalic, and DCPD resins. It further divides the market on the basis of types, industry verticals, and geography. The report analyses the market for unsaturated polyester resins with respect to drivers, opportunities, and winning imperatives related to the industry.

This market is expected to reach USD 2.13 Billion by 2020 from USD 1.78 Billion in 2015, and is poised to grow at a CAGR of 3.6% during the forecast period.

The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018. Factors such as the growing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99, are driving market growth.

Global Radiopharmaceuticals Industry Analysis http://www.reportsnreports.com/reports/274695-global-radiopharmaceuticals-market-insight.html . The new innovations in nuclear medicine to target coronary heart disease, Alzheimer’s disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future. The other segment of the market is the therapeutic segment, which accounts for the remaining 10%.

The nuclear medicine is an intricate branch of medical science that uses radiopharmaceuticals for detection and diagnostic procedures. The radiopharmaceuticals consist of radioisotopes produced through particle accelerator such as the medical cyclotron and are used for targeted therapy, detection based imaging and therapeutics. With advancement in medical technology, the imaging and diagnostic devices have evolved significantly.

According to the latest research report by IMARC Group, The global alpha emitter market size reached US$ 1,476.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 10,975.8 Million by 2032, exhibiting a growth rate (CAGR) of 24.22% during 2024-2032. More Info:- https://www.imarcgroup.com/alpha-emitter-market

Positron Emission Tomography Market report gives attention to market segmentation, market size, and forecast of 2023-2032 to help stakeholders in making a good decision for the future investments. Urinary Catheters industry report segmented into types, application, and regions with providing production, revenue, import/export.

The global radiopharmaceuticals market size is projected to reach USD 9.54 billion by 2026. According to a report published by Fortune Business Insights, titled “Radiopharmaceuticals Market Size, Share & Industry Analysis, By Type (PET Radiopharmaceuticals, SPECT Radiopharmaceuticals), By Application (Neurology, Cardiology, Oncology, and Others), By End User (Hospitals & Clinics, Diagnostic Centres, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 4.86 billion in 2018. Driven by increasing number of successful clinical trials, the market will exhibit a CAGR of 9.0% from 2019-2026. For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/nuclear-medicine-radiopharmaceuticals-market-101812

Lecture at European School on Nuclear Chemistry and Industry

According to the latest research report by IMARC Group, The global positron emission tomography market size reached US$ 1,084 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,512 Million by 2028, exhibiting a growth rate (CAGR) of 5.9% during 2023-2028. More Info:- https://www.imarcgroup.com/positron-emission-tomography-market

Looking forward, the positron emission tomography (PET) market value is projected to reach a strong growth during the forecast period (2022-2027). More info:- https://www.imarcgroup.com/positron-emission-tomography-market

The U.S. Market for Urgent Care Centers http://www.aarkstore.com/reports/The-U-S-Market-for-Urgent-Care-Centers-14692.html

Indigenous Tc-99m Generator Production for Nuclear Medicine ... 1. Dr. Tsujii, Japanese leader of the FNCA project on radiation oncology will ...

Looking forward, the positron emission tomography market value is projected to reach a strong growth during the forecast period (2021-2026). More info:- https://www.imarcgroup.com/positron-emission-tomography-market

Radiopharmaceutical Market Research Report: Information by Type (Diagnostic Type and Therapeutic Type), Type of Test (Bone Scan, Myocardial Perfusion Scan, Parathyroid Scan, Renal Nuclear Medicine Scan, Lung Scan, Gallium Scan, White Blood Cell Scan, Hepatobiliary Scan and Cerebral Perfusion Scan), Application (Oncology, Cardiology, Neurology and Urology), Route of Administration (Oral and Intravenous), End User (Hospitals, Diagnostic Centers and Research Institutes) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2023 Read More @ https://www.marketresearchfuture.com/reports/radio-pharmaceutical-market-1650

The Global Radiopharmaceutical Market is expected to register 8.7% CAGR to reach USD 10,473.88 Million by 2023. Read More @ https://www.marketresearchfuture.com/reports/radio-pharmaceutical-market-1650

Title: Applications of Nuclear Technology Author: Polaris Last modified by: Peter Chieh Created Date: 2/18/2001 1:36:46 PM Document presentation format

Part 2: Practical Applications of Radionuclides. Current Radiopharmaceuticals ... Longer alkyl chain (X,Y, Z) attenuate liver uptake. Phenyl ring (Lipophillic) ...

Neither GE nor Amersham undertakes any obligation to update the forward-looking ... Positions GE for a New Chapter in Diagnostic Medicine ...

Title: Necsa CIT Last modified by: PMG Created Date: 9/6/2005 9:36:20 AM Document presentation format: On-screen Show Other titles: Arial Tahoma Wingdings Times New ...

Many manufacturers produce cyclotron radionuclides themselves ... EBCO TR-30 Cyclotron. Other Radionuclides Produced in Adequate Quantities by Foreign Reactors ...

Being Relevant in Tough Times TRIUMFs FiveYear Plan